Produktbild: Handbook of Cancer and Immunology

Handbook of Cancer and Immunology

Fr. 7’723.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Set mit diversen Artikeln

Erscheinungsdatum

07.08.2025

Abbildungen

CII, 758 illus., 706 illus. in color. In 10 volumes, not available separately., schwarz-weiss Illustrationen, farbige Illustrationen

Herausgeber

Nima Rezaei

Verlag

Springer

Seitenzahl

8747

Maße (L/B)

23.5/15.5 cm

Farbe

Marine

Auflage

1st ed. 2025

Sprache

Englisch

ISBN

978-3-031-40121-3

Beschreibung

Portrait

Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research and Technologies, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the Founder of the Universal Scientific Education and Research Network (USERN). Prof. Rezaei supervised more than two hundred research projects and designed and participated in several international collaborative projects. Prof. Rezaei is the editor, editorial assistant, or editorial board member of more than fifty international journals. He edited more than one hundred international books, presented more than a thousand lectures in congresses/meetings, and published more than 1,500 scientific papers in the international journals.

Produktdetails

Einband

Set mit diversen Artikeln

Erscheinungsdatum

07.08.2025

Abbildungen

CII, 758 illus., 706 illus. in color. In 10 volumes, not available separately., schwarz-weiss Illustrationen, farbige Illustrationen

Herausgeber

Nima Rezaei

Verlag

Springer

Seitenzahl

8747

Maße (L/B)

23.5/15.5 cm

Farbe

Marine

Auflage

1st ed. 2025

Sprache

Englisch

ISBN

978-3-031-40121-3

Herstelleradresse

Springer Heidelberg
Tiergartenstr. 17
69121 Heidelberg
DE
buchhandel-buch@springer.com

Kundinnen und Kunden meinen

0 Bewertungen

Informationen zu Bewertungen

Zur Abgabe einer Bewertung ist eine Anmeldung im Konto notwendig. Die Authentizität der Bewertungen wird von uns nicht überprüft. Wir behalten uns vor, Bewertungstexte, die unseren Richtlinien widersprechen, entsprechend zu kürzen oder zu löschen.

Die Bewertungen sind nach Format, Anzahl Sterne und Datum sortiert.

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kund*innen durch Ihre Meinung

Kundinnen und Kunden meinen

0 Bewertungen filtern

  • Produktbild: Handbook of Cancer and Immunology
  • T cell metabolism and its regulation by checkpoint molecules.- Tumor evasion of the immune system: the role of INF and TNF in cancer.- Intra-tumor cell heterogeneity: different immune responses for different cells.- Epithelial-mesenchymal plasticity, a link between inflammation and cancer metastasis.- Spatial technologies: a game changer to study tumor microenvironment.- Advances in tumor microenvironment immuneprofiling.- Immunodiagnostics: A perspective of tumor-specific antigen expression, specificity, and stability.- Immunohistochemistry as a tool to guide diagnosis, treatment, and prognosis in brain tumors.- Immune check point inhibitors and anti-angiogenic therapy for cancer.- Immune checkpoint inhibitors in unresectable hepatocellular carcinoma patients.- Synthetic-based Tumor-infiltrating lymphocytes (TILs) in adoptive cell therapies.- Development of next-generation antibody therapeutics using DDS and molecular imaging.- Immunotherapy for triple-negative breast cancer.- Immunotherapy for endocrine cancers.- Novel cancer treatment using oncolytic virus therapy.- Lysine acetylation inhibitors (KATi) as novel therapeutics.- CRISPR-Cas9 in personalized treatment in cancer.- Antibody-functionalized nanoparticles for targeted drug delivery in cancer therapy.- Challenges in computational pathology of biomarkers-driven predictive and prognostic immunotherapy.- Diagnosis and management of toxicities associated with immunotherapy in cancer.